Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takemoto, Y.
Right arrow Articles by Kojiro, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takemoto, Y.
Right arrow Articles by Kojiro, M.
Clinical Cancer Research Vol. 10, 7418-7426, November 1, 2004
© 2004 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Antiproliferative Effects of Interferon-{alpha}Con1 on Ovarian Clear Cell Adenocarcinoma In vitro and In vivo

Yumi Takemoto1,2, Hirohisa Yano1, Seiya Momosaki1, Sachiko Ogasawara1, Naoyo Nishida1,2, Sakiko Kojiro1,2, Toshiharu Kamura2 and Masamichi Kojiro1

Departments of 1 Pathology and 2 Obstetrics and Gynecology, Kurume University School of Medicine, Research Center of Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University, Kurume, Fukuoka, Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: We examined the antiproliferative effect of IFN-{alpha}Con1 and its mechanism on ovarian clear cell adenocarcinoma in vitro and in vivo.

Experimental Design: (a) The effects of IFN-{alpha}Con1 on growth, morphology, cell cycle, and type I IFN-{alpha} receptor (IFNAR-2) expression were examined on two ovarian clear cell adenocarcinoma cell lines (KOC-5C and KOC-7C) in vitro. (b) KOC-5C or KOC-7C cells were transplanted into nude mice, and changes in tumor volume, tumor weight, apoptosis, necrosis, and microvessel density were investigated. The expression of angiogenesis factors was examined in the serum and the developed tumors.

Results: Both cell lines expressed IFNAR-2 mRNA, but its protein was detected only in KOC-7C. In KOC-7C cells, antiproliferative effects were observed in a time- and dose-dependent manner and cell division was blocked at the S phase. The KOC-7C tumors showed decreases in tumor volume and weight; a decreasing tendency in basic fibroblast growth factor (bFGF), vascular endothelial growth factor, and interleukin (IL)-8 protein expression in the tumor; a significant decrease in bFGF and IL-8 protein expression in the serum, and of microvessel density; and significant increase in apoptosis and necrosis in the tumor. In the KOC-5C tumors, these in vitro and in vivo changes were not apparent, and the antiproliferative effects of IFN-{alpha}Con1 were not obvious.

Conclusions: IFN-{alpha}Con1 suppresses tumor proliferation by inducing apoptosis, blocking the cell cycle, and inhibiting tumor angiogenesis. Our findings show that the clinical efficacy of IFN-{alpha}Con1 can be predicted by examining IFNAR-2 expression on tumor cells, and the efficacy of IFN-{alpha}Con1 treatment can be evaluated by measuring serum bFGF and IL-8 levels.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The frequency of ovarian carcinoma in Japan has increased remarkably from 0.8 in 100,000 females in 1950 to 5.4 in 1990. Ovarian carcinoma is quite malignant, and the death rate is the highest among malignant gynecologic tumors. Diagnosis and therapeutic treatment are also difficult because they vary in malignancy and histologic type. Major histologic types of ovarian carcinoma are serous, mucinous, endometrioid, and clear cell. Sugiyama et al. (1) reported that clear cell carcinoma presents biological features different from other ovarian carcinomas. Clear cell carcinoma is characterized with poor prognosis that is worse than the other types, high detection rate at stage I, resistance to chemotherapy (mainly cisplatin), and frequent association with endometriosis. The frequency of clear cell adenocarcinoma (CCA) is thought to be 5–10% of all ovarian carcinoma in Western countries, and it is higher in Japan. Currently, a combination of paclitaxel and carboplatin is well known as a postoperative chemotherapy for ovarian carcinoma, but this therapy is not efficacious for CCA (2) ; thus, researchers have been seeking other remedies.

Recent studies reveal the involvement of angiogenesis in the infiltration and proliferation of ovarian carcinoma, and the clinical application of IFN, which is an angiogenesis prohibitor for ovarian carcinoma, has been studied since 1981 (3, 4, 5, 6, 7, 8, 9, 10, 11, 12) . However, the results and reported mechanisms of action vary widely, and consensus on clinical efficacy has not yet been reached. More recently, the suppressive effect of IFN on the proliferation of cultured cell lines and of transplanted tumor cells on animals has been reported, and the efficacy of IFN in combination with other medicines is indicated (7 , 12, 13, 14, 15, 16) .

IFN was found by Nagano and Kojima in 1954 as a virus-inhibiting factor (17) , and showing virus interference is a phenomenon discovered by Isaac and Lindenmann in 1957 (18) . Among IFNs, IFN-{alpha} possesses various biological activities in addition to antiviral effects (e.g., antiproliferative activity and immunoregulatory activity; ref. 19 ), and it is clinically indicated for renal cancer and leukemia (20, 21, 22) . Reported mechanisms of the antitumor effects of IFN-{alpha} are the direct suppressive effect on tumor proliferation and indirect effects such as the enhancement of tumor killing through the activation of immune cells and inhibition of tumor growth through the suppression of angiogenesis (23, 24, 25, 26, 27) .

Consensus interferon (IFN-{alpha}Con1) is a wholly synthetic Type 1 IFN, developed by scanning several IFN-{alpha} nonallelic subtypes and assigning the most frequently observed amino acid in each position (28) . Compared with other IFN-{alpha} species, IFN-{alpha}Con1 shows more potent antiproliferative effects and NK cell activation activity (29) , and it is expected to be efficacious in cancer treatment. This study investigates (a) its antiproliferative effects on ovarian CCA in vitro and in vivo, (b) the mechanism of its antiproliferative action, (c) the expression of IFN-{alpha} receptors, and (d) the relationship between the expression of the angiogenesis factor and IFN-{alpha}Con1.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Ovarian CCA Cell Lines and Culture Conditions.
The human ovarian CCA cell lines KOC-5C and KOC-7C were established in the culture as described elsewhere (30) . These cell lines were grown in DMEM (Nissui Seiyaku Co., Japan) supplemented with 10% heat-inactivated (56°C, 30 min) fetal bovine serum (Bioserum, Victoria, Australia), 100 units/mL penicillin, 100 µg/mL streptomycin (Life Technologies, Inc., Gaithersburg, MD) and 12 mmol/L sodium bicarbonate, in a humidified atmosphere in 5% CO2 in air at 37°C.

Reagents.
IFN-{alpha}Con1 (Advaferon) was kindly provided by Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, Japan). Specific activity of the IFN-{alpha}Con1 was 1 x 109 IU/mg protein. Monoclonal antihuman type II IFN receptor (IFNAR-2; IgG, clone ANOC4866) was kindly provided by Cellular Technology Institute, Otsuka Pharmaceutical Co., Ltd. (Tokushima, Japan). The other antibodies were purchased from the following manufacturers: (a) fluorescein isothiocyanate-conjugated goat antimouse immunoglobulin and anti-BrdUrd antibody, Becton Dickinson Immunocytometry System (San Jose, CA); (b) control normal mouse IgG1 antibody, DAKO (Glostrup, Denmark); (c) monoclonal antihuman vascular endothelial growth factor (VEGF) antibody and monoclonal antihuman interleukin (IL)-8-fluorescein antibody, R&D System (Minneapolis, MN); and (d) antihuman basic fibroblast growth factor (bFGF) monoclonal antibody, Wako Pure Chemical Industries, Inc (Tokyo, Japan).

Analysis of bFGF, IL-8, VEGF, and IFNAR-2 mRNA Expression by Reverse-Transcription-PCR.
Reverse transcription-PCR analysis for bFGF, IL-8, VEGF, and IFNAR-2 were described in our previous reports (31, 32, 33, 34, 35) in detail. The IFNAR-2gene has been reported to produce four different transcripts that encode three different forms of IFNAR-2(36) . The specific primers reported by Lutfalla et al. (36) were used to amplify IFNAR-2a and IFNAR-2ccDNAs, and one of the two IFNAR-2bcDNAs (31 , 32) . The PCR product (5 µL) was electrophorased with a 2% NuSieve agarose gel (FMC Bioproducts, Rockland, ME) that contained 0.5% ethidium bromide, and specific DNA bands were examined under a UV transilluminator.

Flow Cytometric Analysis for bFGF, IL-8, VEGF, and IFNAR-2.
Flow cytometric analysis for bFGF, IL-8, VEGF, and IFNAR-2 was done as described in our previous reports (31, 32, 33, 34, 35) . Briefly, after cell fixation and permeabilization, cell suspension (4 x 105 cells/tube) was reacted with monoclonal anti-bFGF antibody, anti-IFNAR-2 antibody (final concentration, 10 µg/mL), monoclonal anti-IL-8 antibody, anti-VEGF antibody (final concentration, 50 µg/mL), or an appropriate control antibody, except for the IL-8 samples, the cells of which were reacted with FITC-conjugated goat antimouse IgG. All samples were analyzed with a FACScan (Becton Dickinson Immunocytometry System).

Observation of Morphological Changes.
For light-microscopic observation, cells were seeded on Lab-Tek Tissue Culture Chamber Slides (Nunc, Inc., Roskilde, Denmark), cultured with IFN-{alpha}Con1 (0, 1,000, or 4,000 units/mL) for 72 hours, fixed in Carnoy’s solution for 10 minutes, and then stained with H&E.

Effect of IFN-{alpha}Con1 on the Proliferation of Ovarian CCA Cell Lines.
The effect of IFN-{alpha}Con1 on the proliferation of cells was investigated with colorimetric assays with MTT [3-(4,5-dimethylthiazol-2yl-yl)-2, 5-diphenyltetrazolium bromide] cell growth assay kits (Chemicon International, Inc., Temecula, CA) as described in our previous report (31 , 37) . Briefly, cells (5 x 103 cells/well) were seeded on 96-well plates (Nunc), cultured for 24 hours, and then the medium was replaced into a fresh 100 µL medium alone or a medium containing IFN-{alpha}Con1 (0, 250, 1,000 or 4,000 units/mL). After 24, 48, 72, or 96 hours, viable cell numbers were counted. Eight samples were used in each experiment, and each experiment was repeated at least 3 times.

Cell Cycle Analysis.
Cells were cultured with or without IFN-{alpha}Con1 (1000 or 4000 units/mL) for 24, 48, 72, or 96 hours, labeled with 10 µmol/L BrdUrd for 30 minutes, fixed in 70% cold ethanol at 4°C overnight, and stained with anti-BrdUrd antibody and propidium iodide (Sigma Chemical Co., St. Louis, MO) with the technique described elsewhere (37) . The stained cells were analyzed with a FACScan.

Effect of IFN-{alpha}Con1 on Ovarian CCA Cell Proliferation in Nude Mice.
The ovarian CCA cells KOC-5C and KOC-7C (1 x 107 cells/mouse) were transplanted subcutaneously into 5-week-old female BALB/c athymic nude mice (Clea Japan, Inc., Osaka, Japan). On the 18th post-transplantation day when tumor formation was confirmed, the mice were divided into four groups (n = 5–7 each) in a manner to equalize the mean tumor diameter of every group. Each mouse received a subcutaneous injection of 0.1 mL of PBS containing either 0, 1 x 104, 1 x 105, or 1 x 106 IU of IFN-{alpha}Con1 for 14 consecutive days. The lowest concentration (1 x 104 IU/mouse) was about 1.3 times greater than the clinical dose for chronic hepatitis C. Tumor size was measured in two directions using calipers 3 times per week, and tumor volume (mm3) was estimated as "length x (width)2 x 0.5." The tumors were resected 2 weeks after the initial injection. After measuring the weight, the tumors were used for morphological studies (e.g., H&E staining and immunohistochemistry) and ELISA analysis. The number of apoptotic cells was counted in ten 0.25 mm2-areas within an H&E-stained specimen, and the average number per area was obtained. In the counting, necrotic areas were excluded. In addition, the appearance of the apoptotic cells was confirmed with the TUNEL [terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labeling] technique (Apoptag Peroxidase In Situ Apoptosis Detection kit, Chemicon International Inc.). The area of necrosis in each specimen was quantified with an NIH image 1.61 software program. Each animal experiment was repeated at least twice.

The animals were treated in accordance with the "Guide for the Care and Use of Laboratory Animals" (NIH, publication no. 86–23, revised 1985).

Quantification of Microvessel Density.
Double immunohistochemical staining was done with antimouse endothelial cell (anti-CD34) antibody, antihuman {alpha} smooth muscle actin antibody, Histofine simple stain mouse MAX-PO (Rat) kits (Nichirei, Tokyo, Japan) and HistoMouse-plus kits (Zymed Labs, Inc., San Francisco, CA). Histofine simple stain mouse MAX-PO (Rat) kits were used to first immunostain the tumor sections with antimouse endothelial cell antibody, and they were reacted with a mixture of 3,3-diaminobenzidine tetrahydrochloride. We conducted the second staining with antihuman {alpha}-smooth muscle actin antibody by making the section react to the primary antibody, {alpha}-SMA, at 4°C overnight, and by using the HistoMouse-plus kits. The sections were developed with the mixture of a commercial chromogen (VIP) and hydrogen peroxide (Vector VIP Substrate kit, Vector Labs, Inc., Burlingame, CA), and counterstaining was done with hematoxylin. The number of microvessels in a unit area (one mm2) was counted on every section, and the mean number of the group was obtained.

ELISA.
The tumors were cut into pieces, and a pellet pestle was used to homogenize an appropriate amount in 500 µL of ice-cold Ca2+- and Mg2+-free PBS containing 100 µL/mL phenylmethylsulfonyl fluoride. The mixture was centrifuged for 10 minutes (12,000 rpm, 4°C), and the supernatant was stored at –20°C until use. The amount of bFGF, IL-8, and VEGF in the supernatant and serum was measured with the Quantikine ELISA kit (bFGF and IL-8, Amersham Biosciences, Little Chalfont, Buckinghamshire, United Kingdom; VEGF, TECHNE Corporation, Minneapolis, MN). The amount of tissue protein was determined with a bicinchoninic acid protein assay reagent (Pierce, Rockford, IL).

Statistical Analysis.
The differences in tumor weight and tumor volume, the results of the MTT assay and ELISA and microvessel density (MVD) among the groups were compared by ANOVA.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of IFNAR-2, bFGF, IL-8, and VEGF mRNAs.
The two cell lines expressed a 481 bp band. This corresponds to IFNAR-2c, which is the binding subunit and is necessary for IFN-{alpha} to express its effects. The cell lines did not express the 350 and 713 bp bands that correspond to the PCR products of IFNAR-2a and IFNAR-2b, respectively. bFGF and VEGF-A (VEGF165) were expressed in both of the cell lines. The expression of IL-8 was more apparent in KOC-7C (Fig. 1)Citation .



View larger version (58K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Reverse transcription-PCR analysis of the expression of IFNAR-2, bFGF, IL-8, and VEGF-A mRNAs in the ovarian CCA cell lines KOC-5C and KOC-7C. The PCR products were electrophoresed in a 2% (for bFGF, IL-8 and VEGF-A) or 4% (for IFNAR-2) NuSieve agarose gel and were stained with ethidium bromide. Lane M shows a 100 bp ladder, which was used as the DNA molecular-weight marker. The positions of the expected size of intact products are indicated.

 
IFNAR-2 expression on the cell surface was undetectable on KOC-5C cells, whereas IFNAR-2 expression was detectable at a low level on KOC-7C cells (positive cell rate, 4.1%). The cells that were positive for bFGF and VEGF accounted for 66.8% and 12.0%, respectively, in KOC-5C, and the rates in KOC-7C were 33.4% and 6.3%, respectively. IL-8 expression was detected at a very low level, i.e., 3.0% in KOC-5C and 3.7% in KOC-7C (Fig. 2)Citation .



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Flow cytometric analysis of IFNAR-2, bFGF, IL-8, and VEGF-A. These factors were expressed on the ovarian CCA cell lines KOC-5C and KOC-7C. Staining with specific antibodies or the control antibody is shown by the solid and the dotted line, respectively. IFNAR-2 expression on the cell surface was undetectable in KOC-5C but detectable at a low level in KOC-7C (positive cell rate, 4.1%). The rate of cells that were positive in KOC-5C for bFGF, VEGF, and IL-8 was 66.8, 12.0, and 3.0%, respectively, and 33.4, 6.3, and 3.7% in KOC-7C.

 
Effects of IFN-{alpha}Con1 on Apoptosis, Proliferation, and the Cell Cycle.
Seventy-two hours after the addition of IFN-{alpha}Con1 to the culture medium, no remarkable morphological changes were observed on KOC-5C, whereas KOC-7C presented apoptosis-specific changes such as shrinkage of the cytoplasm, nuclear concentration, chromatin condensation, and nuclear fragmentation in a dose-dependent manner (data not shown).

The proliferation of both KOC-5C and KOC-7C was suppressed with IFN-{alpha}Con1, and it was more remarkable in KOC-7C. In KOC-5C, suppression was observed 48 hours or later after the addition of IFN-{alpha}Con1, and suppression at the 72nd hour was substantial compared with the 24th hour (P < 0.001). The cell number decreased by 16% at maximum in the group that had 1,000 or 4,000 units/mL of IFN-{alpha}Con1 compared with the control (P < 0.05, P < 0.001). In KOC-7C, suppression was observed 24 hours or later after the addition of IFN-{alpha}Con1, the effects increased in a time- and dose-dependent manner, and the cell number decreased by 45% at maximum (P < 0.001; Fig. 3Citation ).



View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Effect of IFN-{alpha}Con1 on the growth of ovarian CCA cell lines. Cells (5,000 cells/well) were seeded on 96-well plates and incubated in a medium with or without IFN-{alpha}Con1 (250–4000 units/mL) for 24 to 96 hours. The relative viable cell number was calculated as a percentage of the viable cell number per experimental well to the number in the corresponding control culture. Significant differences between the values for the experimental wells and their corresponding control wells are as follows: *P < 0.001, **P < 0.05. The error bar represents SD. The arrows indicate the concentration of IFN-{alpha}Con1 (units/mL). {diamondsuit}, 24 hours; {blacksquare}, 48 hours; {circ}, 72 hours; •, 96 hours.

 
In KOC-7C, the ratio of cells in the S phase tended to increased, and that in the G1 phase tended to decreased slightly under the IFN-{alpha}Con1 treatment compared with the control at any time point during the 24–72 hours after the addition of 1,000 or 4,000 units/mL of IFN-{alpha}Con1 to the cultures (Fig. 4)Citation . The experiment was done twice, and almost the same results were obtained.



View larger version (43K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Time course of changes in the cell cycle of the ovarian CCA cell line (KOC-7C) cultured with 1,000 or 4,000 units/mL of IFN-{alpha}Con1 or with medium alone (control). The cells were labeled with BrdUrd (30 minutes, 37°C), fixed, stained with anti-BrdUrd antibody and propidium iodide, and analyzed with a FACScan. The contour plots show the effect of IFN-{alpha}Con1 on the cell cycle of KOC-7C. The data represent the percentages of the cells in the S phase.

 
Effects of IFN-{alpha}Con1 on Proliferation of Ovarian CCA in Nude Mice.
Figure 5Citation summarizes the chronological changes in estimated tumor volume. The volume of the KOC-5C tumors decreased slightly (although not significantly) when 1 x 106 units/mouse of IFN-{alpha}Con1 was administered. The volume of the KOC-7C tumors decreased markedly in a time- and dose-dependent manner, and the difference in tumor volume among the groups became apparent from the 8th day of IFN-{alpha}Con1 treatment (P < 0.05, between the control and each IFN-{alpha}Con1 group, and between 1 x 104 units/mouse and 1 x 106 units/mouse).



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Changes in estimated tumor volume. KOC-5C and KOC-7C cells were transplanted subcutaneously to nude mice, and 0.1 mL of IFN-{alpha}Con1 diluted with PBS into 1 x 104, 1 x 105, or 1 x 106 units/mouse or 0.1 mL of PBS was injected subcutaneously for 14 consecutive days from the 18th post-transplantation day (arrow) when tumor formation was confirmed. The mice were sacrificed on the 32nd day. *P < 0.05, **P < 0.001, and ***P < 0.0001 by ANOVA. The error bar represents SD. The arrows indicate the days. {diamondsuit}, 0 units/mL; {blacksquare}, 1 x 104 units/mL; {circ}, 1 x 105 units/mL; •, 1 x 106 units/mL. Each animal experiment was repeated at least twice, and almost the same results were obtained. The figures show representative results.

 
The weight of the KOC-5C tumors increased in the 1 x 105 units/mouse group, but there were no changes in the other dosage groups. The weight of the KOC-7C tumors decreased dramatically in a dose-dependent manner, and the weight of the 1 x 106 units/mouse group decreased by approximately 81% compared with the control (P < 0.05, between every IFN-{alpha}Con1 group and the control, Table 1Citation ).


View this table:
[in this window]
[in a new window]

  		Table 1 Treatment of human ovarian CCA that was growing subcutaneously in nude mice

 
H&E staining revealed that the appearance of apoptotic cells and necrosis in the KOC-5C tumors of the groups with IFN-{alpha}Con1 treatment was no different from that of the control group. On the other hand, in the KOC-7C tumors, the number of apoptotic cells as well as the number of necrotic lesions increased significantly in a dose-dependent manner (P < 0.01; Fig. 6Citation ; Table 2Citation ).



View larger version (86K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Apoptosis and necrosis (H&E staining, x40). On the 32nd day, tumors of the KOC-5C and KOC-7C cells were resected, fixed in formalin, prepared in paraffin sections, and underwent H&E staining. In the KOC-7C tumors, the number of apoptotic cells and necrosis decreased significantly with 1 x 106 units of IFN-{alpha}Con1. The TUNEL technique was used to confirm the appearance of apoptotic cells.

 

View this table:
[in this window]
[in a new window]

  		Table 2 Apoptosis and necrosis in human ovarian CCA that was growing subcutaneously in the control and IFN-{alpha}Con1 (1 x 106 units) treated nude mice

 
MVD in a unit area (one mm2) of the KOC-5C tumors did not show significant differences between the groups with or without IFN-{alpha}Con1, whereas MVD within the KOC-7C tumors decreased significantly with 1 x 106 units of IFN-{alpha}Con1 (P < 0.005). MVD on the margin of the KOC-7C tumors did not decrease (Table 3)Citation .


View this table:
[in this window]
[in a new window]

  		Table 3 Microvessel density in human ovarian CCA that was growing subcutaneously in the control and IFN-{alpha}Con1 (1 x 106 units) treated nude mice

 
Detection of bFGF, IL-8, and VEGF In vivo with ELISA.
The expression of bFGF, VEGF, and IL-8 in the KOC-5C tumors did not change among the groups with or without IFN-{alpha}Con1 treatment, whereas the KOC-7C tumors presented a decreasing tendency in the expression of bFGF and IL-8, and there was a substantial decrease in VEGF (P < 0.005, Table 4Citation ). The serum levels of the three angiogenesis factors were not affected by IFN-{alpha}Con1 in the nude mice with KOC-5C tumors, whereas in the mice with KOC-7C tumors, IL-8 decreased significantly in the groups that received 1 x 105 (P < 0.05) or 1 x 106 units/mouse (P < 0.01), and bFGF decreased significantly in all dosage groups (P < 0.01 for 1 x 104, P < 0.05 for 1 x 105, and P < 0.001 for 1 x 106; Table 4Citation ).


View this table:
[in this window]
[in a new window]

  		Table 4 ELISA of human ovarian CCA that was growing subcutaneously in nude mice

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In our in vitro experiment, IFN-{alpha}Con1 suppressed the proliferation of both KOC-5C and KOC-7C, and suppression was more obvious for KOC-7C. Previous studies have shown that the mechanisms of growth inhibition by IFN-{alpha} are the induction of apoptosis and the inhibition of cell cycle progression at the S, G2-M, or G1 phase (31 , 38 , 39) . We also examined the mechanism of growth inhibition and found morphological evidence (i.e., in KOC-7C cells) of apoptotic cells increasing in number with the increase in IFN-{alpha}Con1 level. Cell cycle analysis with the double-staining technique with anti-BrdUrd antibody and propidium iodide showed that the ratio of cells in the S phase tended to increase in a dose- and time-dependent manner. These findings suggest that IFN-{alpha}Con1 directly inhibits the proliferation of KOC-7C by inducing apoptosis, necrosis, and blockage of cell cycle progression at the S phase. However, these changes were not obvious in KOC-5C.

In our in vivo experiment, IFN-{alpha}Con1 induced a remarkable decrease in estimated tumor volume as well as actual tumor weight in the KOC-7C tumors in a dose-dependent manner, but the nude mice with KOC-5C tumors did not show significant differences between the control and the IFN-{alpha}Con1–treatment groups. The mechanism of the in vivo antiproliferative effect was examined by monitoring angiogenesis, the expression of angiogenesis factors, and apoptosis. Well-known angiogenesis factors relating to cancer metastasis and invasion are bFGF (40 , 41) , IL-8 (42 , 43) , VEGF (34 , 44) , and matrix metalloproteinase (45, 46, 47, 48) . IFN-{alpha} is reported to suppress angiogenesis and thus tumor proliferation by decreasing the expression of these factors, mainly of bFGF and IL-8 (40, 41, 42, 43) . We examined this point by measuring the amount of angiogenesis factors expressed in the subcutaneous tumor using ELISA and found a decreasing tendency in bFGF, VEGF, and IL-8 with IFN-{alpha}Con1 treatment. The serum levels of the factors were also measured, and IL-8 and bFGF decreased significantly although VEGF did not. IL-8 decreased in a dose-dependent manner, and bFGF decreased significantly with both a high dose and a low dose of IFN-{alpha}Con1 to a similar degree. These results show that the effects of IFN-{alpha}Con1 vary among the factors and indicate that IFN-{alpha}Con1 reduced the expression of IL-8 and bFGF on tumor cells, thus suppressing angiogenesis in the tumor, having an antiproliferative effect.

MVD in the KOC-7C tumors decreased significantly with high-dose IFN-{alpha}Con1 administration. In this respect, IFN-{alpha}Con1 does not directly inhibit angiogenesis by inducing growth inhibition or apoptosis in mouse endothelial cells because human IFN{alpha}-Con1 does not act on mouse cells. This suggests that IFN-{alpha}Con1 indirectly suppresses angiogenesis by inhibiting the expression of angiogenesis factors in tumor cells. In addition, an increase in apoptosis and necrosis in tumor was morphologically confirmed, and this indicates that IFN-{alpha}Con1 directly induces apoptosis, and indirectly induces necrosis, by suppressing tumor angiogenesis. On the other hand, the KOC-5C tumors did not show substantial changes in the expression of angiogenesis factors or the appearance of apoptosis and necrosis.

The effects of IFN-{alpha} are mediated through interaction with the specific cell-surface receptor, i.e., type I IFN receptor (36 , 49 , 50) . The receptor consists of at least two chains (i.e., AR-1 and AR-2). AR-1 is essential for the expression of a high affinity receptor, and AR-2 is the subunit to which IFN binds. AR-2 also consists of three forms, i.e., short (AR-2b) and long (AR-2c) forms that are trans-membrane proteins and a soluble form (AR-2a) that is secreted outside the cell. These forms are probably produced by exon skipping, alternative splicing of the same gene, or the use of a different polyadenylation position. AR-2c is the most important form for the expression of IFN action as well as for normal IFN binding (36 , 49) . Reverse transcription-PCR showed the expression of IFNAR-2c mRNA, but not of IFNAR-2a or IFNAR-2b mRNAs, on the two ovarian CCA cell lines, and this indicates that the expression levels of AR-2a and AR-2b are low. Flow cytometric analysis revealed the protein expression of AR-2c on KOC-7C but not on KOC-5C. This suggests that IFN-{alpha}Con1 cannot bind with its receptor on KOC-5C because there is little expression of IFNAR-2, and the signal transduction pathway of IFN-{alpha}Con1 is not activated in the cells. This may result in the apparent difference between the two cell lines on the antiproliferative effects of IFN-{alpha}Con1 and its suppression of angiogenesis factors. It can be argued that it is difficult to understand how KOC-7C cells respond to IFN-{alpha} if only 4.1% of the cells expressed IFNAR-2. In our previous study (31) , however, the proliferation of several hepatocellular carcinoma cell lines expressing a comparable level of AR-2c was also suppressed significantly by IFN-{alpha}.

Our findings show that the clinical efficacy of IFN-{alpha}Con1 can be predicted by examining IFNAR-2 expression on tumor cells, and the efficacy of IFN-{alpha}Con1 treatment can be evaluated by measuring serum bFGF and IL-8 levels.

Our study shows the antiproliferative effect of IFN-{alpha}Con1 on ovarian carcinoma; however, IFN treatment for ovarian carcinoma has not yet fully established, and there are only few reports using animal experiments or on the clinical application of CCA. In recent trials, IFN-{alpha} has been used with IFN-{gamma}, retinoid (7 , 16) , IL-2 (20) , or chemotherapy such as 5-fluorouracil (21) and paclitaxel (13) . To fully use the action of IFN-{alpha}Con1, additional studies on combination therapy as well as the suppression of tumor proliferation on other histologic types of ovarian carcinoma are needed. The latter is currently under way using three ovarian serous adenocarcinoma cell lines. In addition, we plan to inject our ovarian carcinoma cell lines into various sites in nude mice, such as the ovary (orthotopic site) and the peritoneal cavity and to examine the antitumor effect of IFN-{alpha}Con1 in different environments.


   ACKNOWLEDGMENTS
 
We sincerely thank Akemi Fujiyoshi for assistance with experiments.


   FOOTNOTES
 
Grant support: in part by the Sarah Cousins Memorial Fund, Boston, Massachusetts, and by a Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Science, Sports and Culture, Japan (No. 13670233).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Yumi Takemoto, Department of Pathology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan. Phone: 81-942-31-7546; Fax: 81-942-32-0905; E-mail: hyumi{at}med.kurume-u.ac.jp

Received 2/16/04; revised 7/28/04; accepted 8/ 4/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sugiyama T, Kamura T, Kigawa J, et al Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer (Phila) 2000;88:2584-2589.
  2. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, EK M, Rice LW, et al Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage 3 disease. Gynecol Oncol 1996;60:412-417.[CrossRef][Medline]
  3. Berek JS. Intraperitoneal immunotherapy for ovarian cancer with alpha interferon. Eur J Cancer 1992;28A:719-721.
  4. Berek JS. Interferon plus chemotherapy for primary treatment of ovarian cancer. Lancet 2000;356:6-7.[CrossRef][Medline]
  5. Berek JS, Markman M, Blessing JA, et al Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Gynecol Oncol 1999;74:48-52.[CrossRef][Medline]
  6. Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 2003;21:168-174.[Free Full Text]
  7. Lindner DJ, Borden EC, Kalvakolanu DV. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res 1997;3:931-937.[Abstract]
  8. Bruzzone M, Rubagotti A, Gadducci A, et al Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patientsG.O.N.O. Gruppo Oncologic Nord Ovest. Gynecol Oncol 1997;65:499-505.[CrossRef][Medline]
  9. Moore DH, Valea F, Walton LA, Soper J, Clarke-Pearson D, Fowler WC, Jr. A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol 1995;59:267-272.[CrossRef][Medline]
  10. Ferrari E, Maffeo DA, Graziano R, Gallo MS, Pignata S, De Rosa L. Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer. Eur J Gynaecol Oncol 1994;15:437-442.[Medline]
  11. Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon. Gynecol Oncol 1992;45:3-8.[CrossRef][Medline]
  12. Bezwoda WR, Golombick T, Dansey R, Keeping J. Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-alpha or interferon-alpha plus chemotherapy in vivo and in vitro. Eur J Cancer 1991;27:1423-1429.
  13. Tedjarati S, Baker CH, Apte S, et al Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res 2002;8:2413-2422.[Abstract/Free Full Text]
  14. Morrison BH, Bauer JA, Kalvakolanu DV, Lindner DJ. Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. J Biol Chem 2001;276:24965-24970.[Abstract/Free Full Text]
  15. Wall L, Burke F, Smyth JF, Balkwill F. The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo. Gynecol Oncol 2003;88:S149-S151.[CrossRef][Medline]
  16. Hu W, Verschraegen CF, Wu WG, et al Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines. Int J Gynecol Cancer 2002;12:202-207.[CrossRef][Medline]
  17. Nagano Y, Kojima Y. Immunizing property of vaccinia virus inactivated by ultraviolets rays. C R Seances Soc Biol Fil 1954;148:1700-1702.[Medline]
  18. Isaacs A, Lindenmann J. Virus interference. I. The interferon Proc R Soc Lond B Biol Sci 1957;147:258-267.
  19. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.[CrossRef][Medline]
  20. Groupe Francais d’Immunotherapie.Negrier S, Escudier B, Lasset C, et al Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-1278.[Abstract/Free Full Text]
  21. Bernhard H, Jager-Arand E, Bernhard G, et al Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial. Br J Cancer 1995;71:102-105.[Medline]
  22. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.Tura S, Baccarani M. Alpha-interferon in the treatment of chronic myeloid leukemia. Blood 1995;85:2999-3002.[Free Full Text]
  23. Torcia M, Lucibello M, De Chiara G, et al Interferon-alpha-induced inhibition of B16 melanoma cell proliferation: interference with the bFGF autocrine growth circuit. Biochem Biophys Res Commun 1999;262:838-844.[CrossRef][Medline]
  24. Milner AE, Grand RJ, Gregory CD. Effects of interferon-alpha on human B cells: repression of apoptosis and prevention of cell growth are independent responses of Burkitt lymphoma lines. Int J Cancer 1995;61:348-354.[Medline]
  25. Thulasi R, Dias P, Houghton PJ, Houghton JA. Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor. Cell Growth Differ 1996;7:531-541.[Abstract]
  26. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grander D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ 1997;8:343-352.[Abstract]
  27. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994;91:1198-1205.[Abstract/Free Full Text]
  28. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996;16:489-499.[Medline]
  29. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 1992;12:55-59.[Medline]
  30. Tomioka Y. Establishment and characterization of three human ovarian clear cell carcinoma cell line. J Kurume Med Assoc 1998;61:323-333.
  31. Yano H, Iemura A, Haramaki M, et al Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999;29:1708-1717.[CrossRef][Medline]
  32. Takayama A, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression of Hu-IFN-alphaR2 chain of type I interferon receptor in human hepatocellular carcinoma and non-cancerous tissues. Int J Mol Med 2000;6:621-627.[Medline]
  33. Ogasawara S, Yano H, Iemura A, Hisaka T, Kojiro M. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 1996;24:198-205.[CrossRef][Medline]
  34. Yamaguchi R, Yano H, Nakashima Y, et al Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 2000;7:725-729.[Medline]
  35. Akiba J, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol 2001;18:257-264.[Medline]
  36. Lutfalla G, Holland SJ, Cinato E, et al Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 1995;14:5100-5108.[Medline]
  37. Yano H, Mizoguchi A, Fukuda K, et al The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res 1994;54:448-454.[Abstract/Free Full Text]
  38. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001;33:346-356.[CrossRef][Medline]
  39. Numa Y, Kawamoto K, Sakai N, Matsumura H. Flow cytometric analysis of antineoplastic effects of interferon-alpha, beta and gamma labelled with fluorescein isothiocyanate on cultured brain tumors. J Neurooncol 1991;11:225-234.[CrossRef][Medline]
  40. Dinney CP, Bielenberg DR, Perrotte P, et al Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58:808-814.[Abstract/Free Full Text]
  41. Singh RK, Llansa N, Bucana CD, Sanchez R, Koura A, Fidler IJ. Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells. Cell Growth Differ 1996;7:397-404.[Abstract]
  42. Oliveira IC, Sciavolino PJ, Lee TH, Vilcek J. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci USA 1992;89:9049-9053.[Abstract/Free Full Text]
  43. Singh RK, Gutman M, Llansa N, Fidler I. J. Interferon-beta prevents the upregulation of interleukin-8 expression in human melanoma cells. J Interferon Cytokine Res 1996;16:577-584.[Medline]
  44. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst (Bethesda) 1990;82:4-6.[Free Full Text]
  45. Slaton JW, Karashima T, Perrotte P, et al Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res 2001;7:2840-2853.[Abstract/Free Full Text]
  46. Kato N, Nawa A, Tamakoshi K, et al Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon beta. Am J Obstet Gynecol 1995;172:601-606.[CrossRef][Medline]
  47. Gohji K, Fidler IJ, Tsan R, et al Human recombinant interferons-beta and -gamma decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells. Int J Cancer 1994;58:380-384.[Medline]
  48. Fabra A, Nakajima M, Bucana CD, Fidler IJ. Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. Differentiation 1992;52:101-110.[CrossRef][Medline]
  49. Domanski P, Witte M, Kellum M, et al Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem 1995;270:21606-21611.[Abstract/Free Full Text]
  50. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987;56:727-777.[CrossRef][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takemoto, Y.
Right arrow Articles by Kojiro, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takemoto, Y.
Right arrow Articles by Kojiro, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online